Introducing Clinical Trials 2.0: An Integrated Solution To Support The Clinical Trials Of The Future
Most scientific discovery begins with a simple question: “What if.?” Indeed, the question has been the genesis of pharmaceutical breakthroughs ranging from the discovery of Aspirin, the introduction of Good Clinical Practices (GCP) to the invention of Electronic Data Capture Systems (EDCs).
Yet “What if?” is not asked often enough in clinical operations. “What if we had today’s technologies 25 years ago when GCP guidelines were adopted? Would we do things differently today?” “What if our resistance to change isn’t rooted in regulations, but in our own reluctance to challenge the status quo?” “What if we design our processes around what technology can do, rather than the other way around?” And lastly, “What if we calculate the cost of not doing something as opposed to the cost of doing it?”
Clinical Trials 2.0: A Fresh Approach to Systems and Data 01 MAR 2021 Monday
This white paper explores the value of taking a fresh approach to clinical data management, its associated systems and ultimately the processes and roles that surround them. With the right technologies in place, companies can re-invent the traditional roles of Clinical Research Associates (CRAs) and Data Managers to reduce trial costs and timelines.
Ideally, in what could be considered “Clinical Trials 2.0”, trial sponsors will have the benefit of one integrated platform used to collect, review, and share relevant data from site systems, patient-home systems and other external sources.
Supplier info centre
Trial underway to help smokers quit; AMR Norfolk looking for participants
and last updated 2021-02-18 14:51:06-05
NORFOLK, Va. â As cases of the more contagious COVID-19 variants continue to multiply across the country, smokers may be more encouraged than ever to kick the habit.
Dr. William Smith said smokers are at increased risk for severe illness from COVID-19.
âPeople with severe lung disease, which is one of the side effects of smoking, are at more risk for COVID,â he said.
Fewer than one in 10 adult smokers successfully quit each year.
A new pill under research could help more people put down the cigarettes for good. The naturally derived drug is called cytisinicline.
Participants needed in Virginia as trial to help smokers quit gets underway
By: WTKR Staff
and last updated 2021-02-18 15:06:23-05
NORFOLK, Va. â As cases of the more contagious COVID-19 variants continue to multiply across the country, smokers may be more encouraged than ever to kick the habit.
Dr. William Smith said smokers are at increased risk for severe illness from COVID-19.
âPeople with severe lung disease, which is one of the side effects of smoking, are at more risk for COVID,â he said.
Fewer than one in 10 adult smokers successfully quit each year.
A new pill under research could help more people put down cigarettes for good. The naturally derived drug is called cytisinicline.